| scholarly article | Q13442814 |
| P50 | author | Ting Pan | Q87641077 |
| P2093 | author name string | Hui Zhang | |
| Kang Wu | |||
| Xin He | |||
| Nan Zhou | |||
| Yiwen Zhang | |||
| Cancan Chen | |||
| Liting Liang | |||
| Yingtong Lin | |||
| Xiaobing Duan | |||
| P2860 | cites work | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | Q21629049 |
| Chaperoned ubiquitylation--crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex | Q24296990 | ||
| The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants | Q24317051 | ||
| Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C | Q24336712 | ||
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b | Q27646953 | ||
| RING domain E3 ubiquitin ligases | Q27860546 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex | Q28210666 | ||
| The ubiquitin code | Q28265104 | ||
| Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes | Q28307762 | ||
| Recognition and processing of ubiquitin-protein conjugates by the proteasome | Q29547616 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Pancreatic cancer | Q29616288 | ||
| Physiological functions of the HECT family of ubiquitin ligases | Q29617293 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane | Q29618478 | ||
| The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif | Q29618938 | ||
| The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity | Q31011512 | ||
| Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro | Q33292215 | ||
| Targeting protein prenylation for cancer therapy | Q33679239 | ||
| Exploring the functional complexity of cellular proteins by protein knockout | Q33715456 | ||
| Oncogenic KRAS signalling in pancreatic cancer | Q34113460 | ||
| Development of siRNA payloads to target KRAS-mutant cancer | Q34287993 | ||
| Signaling pathways in pancreatic cancer. | Q34372474 | ||
| The many faces of Ras: recognition of small GTP-binding proteins | Q34460152 | ||
| Integration of calcium and Ras signalling. | Q34623801 | ||
| A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. | Q36182645 | ||
| APOBEC3G Inhibits MicroRNA-mediated Repression of Translation by Interfering with the Interaction between Argonaute-2 and MOV10 | Q36216069 | ||
| Multimodality treatment of recurrent pancreatic cancer: Mith or reality? | Q36369834 | ||
| Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation | Q36639380 | ||
| Endoscopic evaluation and palliation of pancreatic adenocarcinoma: current and future options | Q36925189 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| The HECT family of E3 ubiquitin ligases: multiple players in cancer development | Q37206488 | ||
| Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing | Q37635847 | ||
| Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation | Q37739922 | ||
| Roles for KRAS in Pancreatic Tumor Development and Progression | Q38102106 | ||
| Tumor adaptation and resistance to RAF inhibitors | Q38160738 | ||
| New insights into ubiquitin E3 ligase mechanism | Q38201970 | ||
| Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein | Q39850218 | ||
| Degradation of HER2 by Cbl-based chimeric ubiquitin ligases | Q40079505 | ||
| Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation | Q40377795 | ||
| Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. | Q41128325 | ||
| Stable suppression of tumorigenicity by virus-mediated RNA interference | Q45730805 | ||
| The biological activity of a recombinantly expressed (His)(6)-tagged peanut allergen (rAra h 1) is unaffected by endotoxin removal. | Q46673262 | ||
| Fluorescent fusion protein knockout mediated by anti-GFP nanobody | Q50506348 | ||
| The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study | Q51758238 | ||
| Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth In Vitro and In Vivo | Q53260084 | ||
| Increasing complexity of Ras signaling | Q53429989 | ||
| Recurrence of exocrine pancreatic cancer--local or hepatic? | Q70496747 | ||
| Recurrence after resection for ductal adenocarcinoma of the pancreas | Q71973040 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 44299-44309 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth | |
| P478 | volume | 7 |
| Q100762044 | Post-translational modification of KRAS: potential targets for cancer therapy |
| Q58566968 | Targeted Intracellular Delivery of Antibodies: The State of the Art |
| Q107113087 | The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι |
Search more.